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Abstract  13 
Papillomaviruses are species- and tissue-specific double-stranded DNA viruses. These viruses cause epithelial tumours  14 
in many animals, including man. Typically, the benign warts undergo spontaneous, immune-mediated regression, most  15 
likely effected by T cells (especially CD4, but also CD8 subsets), whereas humoral immunity can prevent new  16 
infections.  Some papillomavirus infections fail to regress spontaneously, and others progress to malignant epithelial  17 
tumours. Additionally, the impact of these lesions is greater in immunosuppressed individuals. Many therapies are  18 
ineffective, and there is much interest in the potential for immunological intervention in papillomavirus infections of  19 
man and animals. Vaccination can be achieved with ‘live’ virus, formalin-inactivated virus, synthetic virus-like  20 
particles, and DNA vaccination.  There has been much recent progress in the development of such vaccines for  21 
papillomavirus infections in the rabbit, ox and dog. Success in these animal models suggests that similar approaches  22 
may prove useful for prophylactic or therapeutic vaccination against the important human papillomaviruses involved in  23 
the development of cutaneous and anogenital warts, laryngeal papillomatosis, and cervical cancer.  24 
  25 
1. INTRODUCTION  26 
Papillomaviruses are highly species- and tissue- specific non-enveloped viruses, with a circular, double-stranded DNA  27 
genome of approximately 8 kilobases. They infect a wide variety of species, causing both benign and malignant  28  
  2 
epithelial proliferations. Although the benign lesions (warts) typically undergo spontaneous regression, some infections  29 
have a prolonged or more extensive clinical course, occasionally progressing to cancer.  The persistent benign warts  30 
can prove troublesome in both domestic animals and man.  The human papillomaviruses are known to cause anogenital  31 
and cutaneous warts, and are known also to be a key factor in the development of cervical cancer.  The impact of these  32 
diseases is huge: anogenital warts are the most common sexually-transmitted viral disease in the United Kingdom  33 
(Anonymous, 1989), and cervical cancer kills approximately 500,000 women every year (Howett et al., 1997; Beutner  34 
and Tyring, 1997).  Improved knowledge of the immunity of papillomavirus infections underpins the development of  35 
effective prophylactic and therapeutic vaccines.  The study of animal papillomaviruses has proved central to the  36 
development of our understanding of the immunology of this important group of viral pathogens.    37 
  38 
The study of animal papillomaviruses has a long history. One hundred years ago M'Fadyean and Hobday (1898) from  39 
the Royal Veterinary College in London undertook some simple transmission experiments using canine oral  40 
papillomavirus (COPV).  Their failure to re-infect a bull terrier after its oral warts had regressed led them to conclude  41 
"the animal is left in a measure protected against a second infection of the same kind".  This review analyses the  42 
historical and recent evidence for such immunity to papillomavirus infections in animals.  43 
  44 
Wart regression  45 
The simultaneous disappearance of many warts in individual rabbits (Kidd, 1938) is evidence for systemic immunity.  46 
After noting the spontaneous regression after 1 to 2 months of experimentally-induced canine oral papillomas (figure  47 
1), M'Fadyean and Hobday (1898) proposed that "the credit claimed for some methods of treatment may be  48 
undeserved”.  Spontaneous regression of papillomas has been reported also in the pig (Parish, 1961), horse (Cook and  49 
Olson, 1951), ox (Knowles et al., 1996), sheep (Hayward et al., 1992), goat (Theilen et al., 1985), white-tailed deer  50 
(Sundberg et al., 1985), Indian elephant (Sundberg et al., 1981), rabbit (Kreider, 1963; Okabayashi et al., 1991) and  51 
opossum (Koller, 1972). This spontaneous and often unpredictable regression of papillomas has allowed many claims  52 
for therapeutic efficacy to flourish.  Historically, some of the more colourful therapies for human warts include rubbing  53 
them with bacon and burying it, or tying knots on a piece of string, again followed by burying the string (Thomen,  54 
1938).  These ‘sympathetic cures’ relied on the belief that the warts could be transferred to some other object which  55 
then decays or is thrown away, taking the disease with it.  Modern opinion on the therapy of papillomavirus infection is  56  
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reviewed elsewhere (Stanley et al., 1997; Phelps et al., 1998).  57 
  58 
Immunity to reinfection  59 
M'Fadyean and Hobday's original observation (1898) that dogs which recover from papillomas are immune to re- 60 
infection has been confirmed by others (DeMonbreun and Goodpasture, 1932; Chambers et al., 1960; Konishi et al.,  61 
1972).  The same phenomenon is seen in the horse (Cook and Olson, 1951), rabbit (Shope, 1933) and cow (Olson et al.,  62 
1960).  Experimentally, dogs cannot be re-infected from three weeks post-infection (Chambers et al., 1960; Konishi et  63 
al., 1972), despite the continued growth of existing warts. This indicates that a form of concomitant immunity exists, as  64 
is the case in cattle (Olson et al., 1960).  Their inability to infect dogs in which warts were regressing prompted  65 
DeMonbreun and Goodpasture (1932) to suggest that it was host immunity which limited wart growth and initiated  66 
regression.  The increased susceptibility of young dogs to COPV infections  (Walder, 1992; DeMonbreun and  67 
Goodpasture, 1932) is further evidence that older animals have acquired immunity from a previous episode of  68 
papillomatosis (Chambers et al., 1960).   69 
  70 
Early work with rabbits demonstrated that although the protective immunity seen in wart-bearing rabbits could be  71 
bypassed by infection with naked DNA or autografting of skin biopsies infected in vitro, even this was not possible on  72 
rabbits whose warts had regressed (Kreider, 1963).  This quite clearly demonstrated a distinction between the ability to  73 
prevent a new infection and the ability to reject an established lesion. Immunity to re-infection is type-specific, as  74 
demonstrated by the ability of bovine papillomavirus (BPV)-2, BPV-5 and BPV-6 infected calves to succumb to  75 
infection with BPV-4 (Jarrett et al., 1990b).  The multiplicity of viral types means that an individual may suffer  76 
successive infections by new viral types, despite the development of immunity to previous infections.  Vaccine design  77 
will have to take into account the many viral types capable of causing disease.   78 
  79 
Immunosuppression and papillomatosis  80 
Early experimental studies failed to demonstrate increased persistence of papillomas in rabbits immunosuppressed  81 
using cortisone (Evans et al., 1962b).  There are, however, occasional case reports of severe or generalised  82 
papillomatosis in animals immunosuppressed by prednisolone.   83 
  84  
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Immunosuppression by corticosteroid therapy was implicated in the extensive oral and cutaneous papillomas of a  85 
young female dog (Sundberg et al., 1994).  The cessation of corticosteroid therapy in conjunction with autogenous  86 
vaccination was followed by lesion regression.  In a further case, similar regression of extensive canine cutaneous  87 
papillomas was seen three weeks after withdrawal of corticosteroid therapy (Le Net et al., 1997).  Long-term anti- 88 
cancer chemotherapy has been associated with widespread canine cutaneous papillomatosis (Lucroy et al., 1998).  89 
Occasionally, severely affected animals show evidence of immunosuppression such as hypogammaglobulinaemia  90 
(Bredal, 1996) or IgM deficiency with impaired T-cell responses (Mill and Campbell, 1992).  Recurrent papillomatosis,  91 
without the usual development of effective immunity, has been reported in the dog (Cierpisz et al., 1993). We have  92 
examined a similar case (figure 2) of severe, recurrent oral and cutaneous papillomatosis (Nicholls and others, in  93 
press).  In this instance, the warts recurred despite the presence of abundant circulating antibodies to the virus,  94 
suggesting that either the animal was being infected by multiple viral types with no cross-reactive immunity, that a  95 
single latent infection was continually reactivating, or that the animal had defective cellular immunity.  The virus was  96 
not an unusually pathogenic variant, as demonstrated by the uncomplicated spontaneous regression of warts after  97 
experimental infection of beagles with the isolated virus. In this and other cases where defective immunity has been  98 
suspected, the animals have not suffered from unusual fungal, protozoal or other infections, suggesting that any defect  99 
may be limited in its effects.  100 
  101 
Papillomavirus infection in the domestic cat has been seen concurrently with feline immunodeficiency virus (FIV)  102 
infection (Egberink et al., 1992).  This mirrors the situation in humans where infection with human immunodeficiency  103 
virus (HIV) is linked with enhanced papillomavirus-associated disease.   Immunosuppression has been reported as a  104 
factor in papillomavirus infections in cattle (Duncan et al., 1975; Campo, 1987; Campo et al., 1994).  Although  105 
Duncan's report is often cited, the original work is a case report describing abundant warts affecting a single one year  106 
old bull.  Evidence of immunosuppression was based only on the lack of lymphocytic invasion within the warts, a  107 
failure to reject the warts after vaccination, and a negative tuberculin skin test following vaccination.  More recent  108 
work has identified a link with bracken ingestion and the development of alimentary cancer, urinary bladder tumours,  109 
and enzootic haematuria in cattle (Campo, 1987; Campo et al., 1992; 1994).  Chronic immunosuppression is thought to  110 
be a result of sesquiterpene pterosins and pterosides found in bracken (Evans et al., 1982, cited in Campo, 1997).   111 
Bracken-fed cattle developed neutropenia, severe enough to result in fatal septicaemia, as well as chronic lymphopenia.   112  
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Bracken-fed cattle developed cutaneous warts associated with BPV-1 or BPV-2 (Campo et al., 1994) and urinary  113 
bladder carcinomas or haemangiomas associated with BPV-2 (Campo et al., 1992).  The immunosuppressing agent  114 
azathioprine has a similar effect in cattle (Campo et al., 1992).  BPV-4 induced tumours in cattle fed on hay did not  115 
spread beyond the injection sites and regressed after a year.  This contrasts with immunosuppressed cattle, in which the  116 
lesions became extensive, extending down the oesophagus to the rumen without regression.  Feeding of bracken in  117 
conjunction with BPV-4 infection predisposes to transformation of the papillomas into carcinomas.  118 
  119 
It is clear that the immune system plays an important role in modulating the severity of papillomavirus-associated  120 
disease.  In order to develop appropriate immunotherapy, it is important to establish which components of the immune  121 
system are involved in prevention or removal of infection.  122 
  123 
2. HUMORAL IMMUNITY  124 
Cross reactive antibodies led to confusing results  125 
Although it is now known that papillomaviruses share common cross-reactive epitopes (Dillner et al., 1991), the  126 
discovery of canine antibodies which precipitated human papillomavirus led earlier workers to conclude that dogs  127 
could transmit human warts (Pyrohnen, 1976). In addition to the discovery of cross-reactive epitopes, it is now known  128 
that there are significant species barriers to cross-infection (Parish, 1961; DeMonbreun and Goodpasture 1932).  129 
  130 
Prevention of infection - neutralising antibodies in animal papillomaviruses  131 
Passive transfer of immune serum prevents new infections but does not affect established lesions  132 
In dogs recovering from oral papillomas, the ability of antibodies to neutralise infection was demonstrated 40 years ago  133 
by Chambers and others (1960).  A key observation was that despite its ability to neutralise infection, passively- 134 
transferred immune serum failed to enhance papilloma regression. This indicated a role for cellular, rather than  135 
humoral, immunity in wart clearance.  Shortly after Chambers' work in the dog, Parish (1962) established that  136 
neutralising antibodies were present in pigs injected with a wart extract.  The neutralising ability of the serum was  137 
greatest in animals which had received multiple injections of the extract.  The presence of neutralising antibodies  138 
coincided with immunity to reinfection, again suggesting that humoral immunity played a role in prevention of  139 
infection.  Antibodies to pig warts, raised in rabbits, demonstrated viral antigen in pig warts only at the period of  140  
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maximum growth of the lesion.  Although the significance of this finding may not have been clear at the time, it is  141 
likely that the antibodies were detecting the presence of the viral capsid protein, which is synthesised only in mature  142 
warts.  Papillomavirus capsids are composed of a major (L1) and minor (L2) protein. It is antibodies to these proteins,  143 
especially L1, which prevent infection, as later work with the dog, ox and other animals has shown.  144 
  145 
Other animal papillomavirus infections are associated with the development of antibodies, which can be protective.   146 
The development of serum antibodies was demonstrated in deer experimentally infected with papillomas (Sundberg et  147 
al., 1985).  In a rodent (Mastomys natalensis), viral infectivity was neutralised by preincubation in serum from an  148 
immune animal (Muller and Gissmann, 1978).  Early work by Shope (1937) demonstrated the existence of neutralising  149 
antibodies in rabbits immune to reinfection.  More recently, antibodies to cottontail rabbit papillomavirus (CRPV) L1,  150 
and to a lesser extent L2, have been shown also to have neutralising ability (Lin et al., 1992).  Additionally, passive  151 
transfer of serum from immune rabbits can protect naïve rabbits from infection (Breitburd et al., 1995).    152 
  153 
Antibody development during progression from papilloma to carcinoma – the rabbit model  154 
The rabbit has provided the opportunity to study host antibody responses during progression from papilloma to  155 
carcinoma, assayed using bacterial fusion proteins in an immunoblot.  Antibodies to viral early proteins E1 and E2  156 
(involved in viral DNA replication), as well as E6 and E7 (responsible for altering the host cell cycle to maximise viral  157 
replication), were seen in the papilloma stage, with E1 and E2 antibody levels remaining constant whilst those to E6  158 
and E7 declined later.  There was only a low response to the structural proteins L1 and L2 during the benign phases.   159 
The L1 neutralising epitopes were conformational, since only native fusion proteins blocked immunoprecipitation.   160 
With progression to carcinoma came a marked increase in response to the capsid antigens, without significant changes  161 
in early protein responses (Lin et al., 1993b).  The decline in antibody responses to E6 and E7, and their low antibody  162 
levels compared with those to E2, cannot be explained by differences in levels of expression, because mRNA levels for  163 
E6 and E7 are higher than those for E2, and are the same in papilloma and carcinoma (Wettstein, 1987).  Assuming the  164 
mRNA levels reflect protein expression, it is possible that the difference in antibody levels could reflect tolerance or  165 
impaired MHC presentation of the relevant peptides. Conversely, an abundance of viral antigen could have obscured  166 
antibody levels.  No humoral response to E4 (a protein possibly involved in viral DNA replication or viral release from  167 
cells) or E5 (a protein able to increase cell growth) was seen in either domestic rabbits or cottontail rabbits, although  168  
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E4 mRNA is less abundant than that for L1 and L2 in the rabbit (Nasseri and Wettstein, 1984).  In some regressor  169 
rabbits, E2 was the only antigen which generated a response (Lin et al., 1993b).  Antibody responses to E2 were greater  170 
in rabbits with regressing rather than progressing lesions (Selvakumar et al., 1995a).  The role of E2 as an immunogen  171 
is clearly important in the rabbit infections, although the lack of correlation between E2 antibody levels and regression  172 
suggests a cell-mediated response is more important than a humoral response during regression (Selvakumar et al.,  173 
1995b).  This work further supported the earlier reports that passive transfer of serum from immune rabbits (Evans et  174 
al., 1962a) and dogs (Chambers et al., 1960) does not enhance regression.    175 
  176 
The capsid antigens (L1 and L2) can elicit protective IgG antibodies  177 
The early work on passive transfer has recently been extended.  Passive transfer of serum immunoglobulin from  178 
immune dogs was able effectively to prevent infection in naïve dogs (Suzich et al., 1995).  Assay of serum IgG from  179 
pre-immune and immune dogs, using intact COPV virus as an ELISA reagent, demonstrated the development of IgG  180 
antibodies and neutralising serum in animals with regressing oral papillomas (Ghim et al., 1997a).  The use of native  181 
COPV virions as an ELISA reagent indicated that antibodies to conformational capsid (L1) epitopes were likely to be  182 
the main effective antibody.  Similar results were seen in the ox, in which antibodies to L1, or L1 and L2, were  183 
protective against BPV-4 challenge (Kirnbauer et al., 1996).  These antibodies were not associated with regression of  184 
established lesions.  In addition to these experimental studies, naturally-occurring papillomavirus infections offer  185 
important insight into the role of humoral immunity. For example, the presence of multiple non-regressing crops of  186 
warts in a natural COPV infection, despite the demonstration of high levels of virion-specific antibody (using native  187 
COPV virions as an ELISA reagent), demonstrated that humoral immunity plays little role in wart regression in natural  188 
infections (Nicholls and others, in press).  The findings that, although effective prophylactically, anti-L1 antibodies are  189 
ineffective in wart clearance have important implications for vaccine design.  This is especially true for the syndrome  190 
of recurrent respiratory papillomatosis (RRP) of humans in which the recurrent crops of mucosal papillomas, similar to  191 
those described occasionally in the dog, are unlikely to be treatable by vaccination against the viral L1 protein.    192 
  193 
Mechanisms of antibody-mediated viral neutralisation  194 
Although neutralisation by blocking of viral binding sites appears to be an important mechanism, there seem to be  195 
other modes of antibody-mediated prophylaxis.  The mouse xenograft system, in which target tissue of the appropriate  196  
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species is incubated with its host-specific virus (with or without pre-incubation in immune serum) prior to grafting onto  197 
immunodeficient mice, confirmed the neutralising ability of antibodies, raised in rabbits, to intact CRPV or BPV-1  198 
(Christensen and Kreider, 1990).  Interestingly, it seemed that neutralisation could be achieved despite the virus  199 
attaching to the cell (Christensen et al., 1995).  A similar conclusion was reached by Roden and others (1994a).   200 
Although four monoclonal antibodies to BPV-1 L1 neutralised viral infectivity, only three of them prevented adhesion  201 
to the cell surface.  Antibodies to the amino-terminal of BPV-4 L2 also were shown to have a neutralising effect  202 
despite presence of detectable viral DNA, but no lesion, at the challenge site (Gaukroger et al., 1996).  This agreed with  203 
the suggestion that antibodies to BPV capsid proteins could neutralise virus by a mechanism other than prevention of  204 
adhesion to the cell surface.  That some antibodies can work by virus neutralisation is well illustrated by the work of  205 
Lin and others (1993a).  They showed that antibodies to L1 prevented infection by virus, but not by naked DNA- 206 
induced papillomas, the induction of which effectively bypasses virus neutralisation and interaction with cell-surface  207 
receptors.  This observation was largely pre-empted by much earlier work demonstrating the ability of papilloma- or  208 
carcinoma-bearing rabbits to be re-infected by viral DNA, but not virus, in the face of neutralising antibodies (Evans  209 
and Ito, 1966). The mechanisms by which neutralising antibodies prevent infection have been studied.  Antibodies to  210 
conformational epitopes are required for neutralisation, both in vitro (Roden et al., 1994b) and in vivo (Suzich et al.,  211 
1995).  Although both L1 and L2 antibodies neutralise infection, antibodies against conformational epitopes on L1  212 
VLPs, but not anti-L2 antibodies, prevent virus attachment to the cell (Roden et al., 1994b).  Two antibodies to L1  213 
which neutralise by different mechanisms, with only one preventing attachment to the cell, have been shown to bind to  214 
different sites on the viral capsid (Booy et al., 1998).  Virus binding and internalization is a complex multistep process  215 
(Haywood, 1994), and presumably antibodies to L2 inhibit one of the post-attachment steps such as secondary binding,  216 
virion entry, or uncoating (Unckell et al., 1997).  217 
  218 
In vitro techniques for study of virus neutralisation  219 
Some in vitro systems have been developed for the assay of neutralising antibodies.  The focus-forming ability of  220 
bovine papillomaviruses in NIH/3T3 cell cultures has been used to confirm and map the neutralising abilities of anti- 221 
BPV antibodies (Cason et al., 1993).  A cottontail rabbit epidermal cell line was used to demonstrate type-specific  222 
neutralising activity by monoclonal antibodies to CRPV, but not HPV-11 (Angell et al., 1992).  The neutralisation was  223 
attributed to failure of virus to penetrate the cells, since a reduced amount of CRPV DNA was demonstrated within the  224  
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neutralised cultures.  A further system used BPV-1 virions made in vitro using vaccinia virus-derived L1 and L2, which  225 
self-assemble into virus-like particles (VLPs).  These L1/L2 VLPs were able to package BPV-1 DNA from a cell-line  226 
containing the episomal viral genome, before being used to infect mouse fibroblasts.  Infection was prevented by  227 
neutralising antibody, providing a system in which to investigate virus neutralisation (Zhou et al., 1993). The discovery  228 
that L1 protein alone, expressed in vitro, spontaneously self-assembles into virus-like particles, similar to those seen in  229 
natural infections (figure 3) allowed the creation of reagents for assay of antibody responses in a variety of systems.  230 
Antibodies to yeast-expressed CRPV L1 VLPs have been demonstrated in rabbits, with immune serum capable of  231 
neutralising the virus in vitro (Jansen et al., 1995).    232 
  233 
Synthetic virus-like particles are an important tool  234 
The ability to synthesise virus-like particles in vitro has allowed studies on the role of humoral immunity in human  235 
papillomavirus infections.  Prior to VLP development, antibody responses to only HPV-1 and HPV-11 could be  236 
examined, since they were the only lesions from which sufficient virus could be isolated as the ELISA reagent (Steele  237 
and Gallimore, 1990; Bonnez et al., 1991).  The generation of VLPs allowed studies of the correlation between lesion  238 
status and antibody prevalence (for reviews see Stanley, 1997; Carter and Galloway, 1997).  Despite the progress made  239 
in studies of immunity to human papillomaviruses since the development of VLP-based ELISAs, experimental studies  240 
of animal papillomaviruses continue to provide important data which are difficult to obtain by clinical studies of HPV  241 
infections.  Although not all patients with HPV-associated lesions have detectable antibodies, the proven  242 
immunogenicity of HPVs injected into rabbits (Christensen et al., 1994) suggests that the lack of consistent antibody  243 
response in natural infections in humans reflects poor presentation of viral antigens to the immune system. Similar  244 
work has been undertaken in primates, demonstrating that HPVs are certainly immunogenic under the right conditions  245 
(Lowe et al., 1997).  246 
  247 
Experimental studies in cattle have provided useful insights into possible reasons for the ineffective immunity seen in  248 
many papillomavirus infections. For example, there seems to be good correlation between HPV-16-associated cervical  249 
cancer and the presence of antibodies to E6, E7 and to a lesser extent E2 and E4 (Mann et al., 1990; Dillner et al.,  250 
1994).  The significance of these antibodies is difficult to establish, although antibodies to HPV-16 E7 seem to indicate  251 
a poorer prognosis (Gaarenstroom et al., 1994).  This is of interest in the light of a chronological study of the response  252  
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to E7 in cattle infected with BPV-4 (Chandrachud et al., 1994).  In the BPV-4 study, a response to E7 was seen only  253 
late in the infectious cycle, despite a good response when used as a vaccine, suggesting that the protein is poorly  254 
presented to the immune system in natural infections.  Animal models have demonstrated the presence of neutralising  255 
antibodies to human papillomavirus infections.  HPV-11 virions were neutralised by incubation with specific  256 
polyclonal antiserum (Christensen and Kreider, 1990; Bryan et al., 1997) or monoclonal antibodies (Christensen et al.,  257 
1990), prior to xenografting human skin under the renal capsule in an athymic mouse system. In this procedure, the  258 
immunosuppressed environment permits propagation of HPV-infected xenografts, circumventing the significant  259 
difficulties involved in tissue culture based systems. Using this technique, neutralising antibodies were found to be  260 
directed to external non-linear epitopes.  Virion pseudotypes, using HPV-16 L1 and L2 expressed by recombinant  261 
Semliki forest virus to package BPV-1 DNA, have been used to demonstrate neutralising antibodies against HPV-16  262 
(Roden et al., 1996).  The pseudotype virus is incubated in the test serum prior to assay by focus-formation on  263 
fibroblast cultures.  More recent work used HPV-16 virions generated from murine xenografts for a neutralisation  264 
assay.  The neutralising ability of polyclonal sera, raised in rabbits against HPV VLPs, was assayed by the detection of  265 
early viral transcripts in keratinocytes infected in vitro after the virus had been preincubated in serum (White et al.,  266 
1998).  Neutralisation was type-specific.  267 
  268 
3. CELLULAR IMMUNITY  269 
Cellular immunity and lesion regression  270 
Early work highlighted the different roles of humoral and cellular immunity in papillomavirus infections  271 
As discussed above, the inability to enhance wart regression by passive transfer of immune serum in both the dog  272 
(Chambers et al., 1960) and rabbit (Kidd, 1938; Evans et al., 1962a) suggested that lesion regression was probably  273 
effected by cellular, rather than humoral, immunity.  Further evidence for the role of cellular immunity came from the  274 
resistance of regressor rabbits to infection by naked DNA, which would be able to bypass the immunity due to  275 
neutralising antibodies (Evans and Ito, 1966).  Infection with naked DNA, or autografting of skin biopsies infected in  276 
vitro, was successful on wart-bearing rabbits, whereas viral challenge by scarification was prevented due to  277 
neutralising antibodies.  Once the warts had regressed, DNA and grafting were unable to cause lesions, due presumably  278 
to the development of cellular immunity (Kreider, 1963).  279 
  280  
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Early work by Parish (1962) indicated that cellular immunity played a role in papillomavirus lesion regression.  Parish  281 
noted that injection of wart filtrate into recovered immune pigs resulted in a type of lesion typical of a delayed-type  282 
hypersensitivity reaction.  Parish's conclusion that "It is probable that immunity depends on cellular resistance rather  283 
than on humoral antibodies" now seems to be true as far as wart regression is concerned.    284 
  285 
Wart regression is associated with lymphocyte infiltration  286 
Morphological evidence for the role of lymphocytes in papilloma regression comes from histological demonstration of  287 
cellular infiltrates associated with wart resolution.  This has been noted in many species including the pig (Parish,  288 
1961), horse (Hamada et al., 1990), deer (Sundberg et al., 1985), sperm whale (Lambertsen et al., 1987), ox (Jarrett et  289 
al., 1991; Knowles et al., 1996), and lesions of both cottontail (CRPV) (Kreider, 1963; Okabayashi et al., 1991; 1993a)  290 
and rabbit oral papillomavirus (ROPV) (Harvey et al., 1998).  Analysis of regressing CRPV-induced papillomas  291 
revealed dense T-lymphocyte infiltrates within the epidermis itself, near the basement membrane and in adjacent  292 
dermis (Okabayashi et al., 1991).  In the regressing CRPV lesions, the prominent dermal infiltrates (mostly T  293 
lymphocytes) appeared not to be dividing significantly (as demonstrated by BrdU and Ki67 immunostaining), whereas  294 
the epidermal T lymphocytes were actively cycling.  Additionally, the epidermis of regressing papillomas had a lower  295 
division rate in the upper layers, as measured by the same technique, suggesting that regression was associated with  296 
reduced cell proliferation in the upper layers of the epidermis (Okabayashi et al., 1993a).  The infiltrate in CRPV  297 
lesions was found to consist mostly of CD8+ lymphocytes within the basal and suprabasal layers of epithelium  298 
(Selvakumar et al., 1997) with no CD4+ cells demonstrable.  The absence of CD4+ cells in the CRPV lesions is  299 
remarkable, considering their abundance in regressing COPV (Nicholls and others, unpublished data), BPV (Knowles  300 
et al., 1996) and HPV (Coleman et al., 1994) lesions.  The antibody used to detect CD4+ cells in the rabbit worked well  301 
on spleen sections, but was described as being non-specific on the papilloma sections.  Further work in the rabbit is  302 
needed to confirm these data.  303 
  304 
The infiltrate in regressing BPV-4 papillomas had numerous CD4+ cells in the dermis (Knowles et al., 1996).  In the  305 
more superficial layers of the epithelium there were more CD8+ than CD4+ cells, whilst the basal layers of epithelium  306 
had similar numbers of CD4+ and CD8+ cells.  There were increased TCRγδ+ cells in the superficial epithelium.  The  307 
CD4+ cells were present mostly as clusters subepithelially within the dermis, sometimes surrounded by CD8+ and  308  
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TCRγδ+ cells, but migrating more into the epithelium once the basal lamina had been breached.  In BPV-4 lesions,  309 
lymphocyte numbers correlated with regression, with CD4+ cells being the predominant type. Immunostaining for the  310 
interleukin-2 receptor, an indicator of T cell activation, showed that half of the CD4+ and CD8+ cells, and three  311 
quarters of the TCRγδ+ cells, were positive (Knowles et al., 1996).  Preliminary studies on formalin-fixed, paraffin- 312 
embedded tissues using a CD3 polyclonal antibody (Nicholls et al., 1997) confirmed the presence of numerous T cells  313 
within spontaneously-regressing naturally-occurring canine oral papillomas.  More recent work with experimental  314 
COPV infections has demonstrated a marked influx of CD4+ and CD8+ lymphocytes (figure 4) in spontaneously- 315 
regressing canine oral papillomas (Nicholls and others, unpublished data).  Lymphocyte infiltrates correlated both  316 
spatially and temporally with wart regression. The predominance of CD4+ cells seen in both BPV-4 and COPV lesions  317 
suggests they are playing a key role in clearance of mucosal papillomas.  TH1 CD4+ cells could help clear viral  318 
infections by activating macrophages, or by cytokine-mediated inhibition or killing of infected keratinocytes.   Heavy  319 
infiltration of lymphocytes was seen also in regressing BPV-2 and BPV-4 induced papillomas following vaccination  320 
with L2 and E7 respectively (Jarrett et al., 1991; Campo et al., 1993). There appeared to be some downregulation of  321 
MHC-I on BPV-4 induced cancer cells (Gaukroger et al., 1991), implying that by this mechanism the cells may escape  322 
CTL-mediated killing.  That these observations are applicable to human papillomavirus infection is supported by the  323 
presence of lymphocytic infiltrates in both benign (Coleman et al., 1994) and malignant (Hilders et al., 1994) HPV- 324 
associated lesions, with loss of MHC-I expression in cervical carcinoma (Connor and Stern, 1990).  325 
  326 
Studies of T-cell function in papillomavirus immunity  327 
Skin tests and lymphoproliferative assays demonstrate active cellular immunity  328 
The demonstration of lymphocytic infiltrates in regressing warts clearly indicates their role in lesion clearance.  Several  329 
animal papillomaviruses have provided functional data to support these findings.  Evidence from the CRPV model, in  330 
which seroconversion was not required for regression, indicates that regression is a T-cell mediated event (Selvakumar  331 
et al., 1995b).  The positive skin test in pigs injected with wart filtrate, noted by Parish (1962), was one of the earliest  332 
functional assays of cell-mediated immunity but is still used in more recent studies, sometimes in conjunction with  333 
other functional assays.  For example, the positive skin tests using viral proteins in regressor rabbits (Hopfl et al.,  334 
1993), together with in vitro responses of peripheral blood lymphocytes to viral proteins, clearly indicate active cellular  335 
immunity in the rabbit.  T-cell proliferative responses to the viral E1, E2, E6 and E7 proteins have been seen in the  336  
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rabbit, with those to E2 being the strongest (Selvakumar et al., 1995a; Han et al., 1997).  With progression from  337 
papilloma to carcinoma, an increased lymphoproliferative response to L1 and L2 proteins was seen, despite the low  338 
levels of mRNA for these proteins in the domestic rabbit infections (Lin et al., 1993b; Selvakumar et al., 1994).  The  339 
increased immune response as tumours progress presumably reflects better presentation of epitopes as the malignant  340 
cells disseminate throughout the body.  341 
  342 
Lymphoproliferative assays demonstrated E7-specific T-cells in cattle with naturally-regressing papillomas  343 
(Chandrachud et al., 1994; McGarvie et al., 1995), although the response was much lower than that of cattle vaccinated  344 
with E7 fusion protein, perhaps reflecting poor natural presentation of the antigen.  T-cell responses to L2 proteins have  345 
been demonstrated in the same model (Chandrachud et al., 1995).    346 
  347 
T-cell lymphoproliferative responses to COPV L1 protein have been documented both in infected and VLP-vaccinated  348 
dogs (Cohn et al., 1997), although their role in infections has not been established.  Although destruction of the mature  349 
keratinocytes in which L1 protein is expressed would not by itself clear infection from lower layers of the epithelium, it  350 
is possible that a bystander effect could allow greater impact.  351 
  352 
Rodent models can demonstrate effects of T-cell immunity  353 
Various rodent models have been used to investigate T-cell responses to papillomavirus proteins.  Immunization with  354 
E7 can induce cytotoxic lymphocyte-mediated regression of HPV-16 tumour cells in mice (Chen et al., 1991;  355 
Meneguzzi et al., 1991; Feltkamp et al., 1993).  The ability to use allografts of human lymphocytes in xenografted  356 
SCID mice means that T-cell responses could be examined in this system (Brandsma et al., 1995).  The rodent models  357 
which use tumours to present papillomavirus antigens may not accurately reflect the situation in natural wart infections,  358 
in which immune ignorance of viral antigens may be an important factor.  However, it is possible to mimic the natural  359 
presentation of viral proteins in infected keratinocytes by using mouse models in which a cutaneous graft of transfected  360 
keratinocytes presents papillomavirus proteins in a more biologically-relevant manner (Chambers et al., 1994;McClean  361 
et al., 1993).  Experimentally, most papillomavirus antigens can be made to elicit an immune response, depending on  362 
the mode and route of delivery.  This may not reflect the situation in natural infections, during which viral antigens  363 
may be either shielded from the host immune system, for example by being expressed only superficially, or may be  364  
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expressed on keratinocytes in the absence of costimulatory molecules, leading to anergy (Malejczyk et al., 1997).  In a  365 
murine model, HPV-16 E7 expressing cells cotransfected with B7 caused regression of HPV-16 E7 expressing  366 
tumours, indicating the key role of costimulation in effective antigen presentation (Chen et al., 1992). Because of some  367 
of the uncertainties involved in using these experimental models of cellular immunity, whole animal models based on  368 
infection by the appropriate host-specific virus still play an important role in the study of natural and induced  369 
immunity.  The role of cellular immunity in human papillomavirus infections (reviewed in Malejczyk et al., 1997)  370 
seems similar to that found with animal papillomaviruses. T-cell proliferative responses to both early (de Gruijl et al.,  371 
1996) and late (Shepherd et al., 1996) proteins of HPV-16 have been demonstrated in humans and CTLs specific for E7  372 
peptides have been isolated directly from HPV-associated cervical cancer tissue and regional lymph nodes (Evans et  373 
al., 1997).  Similar studies in HPV-6 associated genital warts have demonstrated CTL activity against both L1 and E7  374 
in infiltrating lymphocytes (Hong et al., 1997).  The association of proliferative responses to E6 and E7 with the ability  375 
to clear infection (Kadish et al., 1997) and the presence of CTL activity against these antigens in a human trial of a  376 
vaccinia virus encoding E6 and E7 (Borysiewicz et al., 1996) suggest some promise for therapeutic vaccination.    377 
  378 
4. HOST FACTORS IN LESION REGRESSION  379 
The outcome of any viral challenge depends on the balance of both viral and host factors.  Variation in lesion duration  380 
and rate of regression is seen in both natural and experimental infections of several species. In the dog, considerable  381 
variability in host immune response to COPV vaccination or infection has been noted (Cohn et al., 1997).  Variation in  382 
antibody and T-cell responses was seen both in dogs vaccinated with COPV L1 VLPs and in dogs infected with COPV.   383 
A similar phenomenon is seen in CRPV infections.  It seems that progression or regression of CRPV-induced warts in  384 
rabbits may be linked to MHC-II allotype (Han et al., 1992).  Studies on rabbits homozygous for three DQA haplotypes  385 
revealed that the outcome of CRPV infection (regression or malignant progression) was linked with the host haplotype  386 
(Breitburd et al., 1997).  In one group of rabbits a fraction of the original warts persisted.  The persisting warts were all  387 
associated with CRPV of the prototype strain (CRPVa), despite it being present as only a minor component in the  388 
pooled inoculum.  In the same individuals, warts arising from a new strain, CRPVb, underwent regression (Salmon et  389 
al., 1997).  The ability of some individuals to reject warts of one strain but not another suggests that the basic  390 
mechanisms of immune recognition are essentially intact and functional, but that antigens from certain viral strains are  391 
ineffectively presented by some hosts.   392  
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  393 
The ability of the same COPV isolate to cause persisting severe infections in some individuals but not others (Nicholls  394 
and others, in press) clearly highlights the importance of host factors in viral infections, as is the case with human  395 
papillomavirus infections.   396 
  397 
5. VACCINATION AGAINST ANIMAL PAPILLOMAVIRUSES  398 
Autogenous vaccination  399 
Autogenous vaccines, prepared by injection of homogenised wart into the original animal, have been used in the ox  400 
(Narayana et al., 1973), dog (Chambers et al., 1960; Cierpisz et al., 1993; Sundberg et al., 1994), goat (Lloyd, 1982;  401 
Rajguru et al., 1988), parrot (Cooper et al., 1986) and rabbit (Evans et al., 1962a).  In some cases the lesions could have  402 
regressed spontaneously but other controlled experiments indicate a positive effect (Evans et al., 1962a).  The  403 
technique is still used today (Agut et al., 1996).  404 
  405 
Heterogenous wart extracts  406 
Early work with rabbits demonstrated that vaccination using a crude wart suspension could generate antiviral  407 
immunity, with serum neutralising antibodies (Shope, 1937).  As well as being protective, both heterogenous and  408 
autogenous crude wart extracts were able to induce regression of warts (Evans et al., 1962a).  409 
  410 
Forty years ago, a crude canine oral papilloma extract, injected with adjuvant intramuscularly or subcutaneously, was  411 
shown to be effective prophylactically (Chambers et al., 1960).  Recent work has confirmed the efficacy of  412 
systemically-administered formalin-inactivated papilloma extract (Bell et al., 1994).  Successful vaccination with "live"  413 
COPV extract, however, was occasionally associated with development of squamous cell carcinoma or other  414 
neoplasms at the injection site (Bregman et al., 1987; Meunier, 1990).  415 
  416 
Crude wart vaccines have a long history of usage in cattle (Olson et al., 1960) and more recent work demonstrated that  417 
homogenised BPV-2 fibropapilloma protected cattle from the homologous viral infection (Jarrett et al., 1990a).  418 
  419 
Purified virus as a vaccine  420  
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Intramuscular vaccination of calves with purified virions of BPV-2 (Jarrett et al., 1990a), BPV-4 and BPV-6 (Jarrett et  421 
al., 1990b) protected animals from subsequent challenge by homologous virus infection.  The ability of BPV-1 to infect  422 
the BPV-6-vaccinated animals demonstrated type-specific protection, an important consideration in papillomavirus  423 
vaccine design considering the multiplicity of viral types within a species.  The demonstration that purified virus was  424 
protective indicated that viral capsid proteins alone could make an effective vaccine.  425 
  426 
Recombinant proteins as vaccines  427 
Bacterial-expressed proteins and CRPV vaccination  428 
Vaccination studies in rabbits showed both L1 and L2 fusion proteins to be protective, accompanied by a neutralising  429 
antibody response which was greater for L1 than L2 (Lin et al., 1992).  Presumably critical conformational epitopes  430 
can be retained in the L1 and L2 fusion proteins.  The role of conformational epitopes was highlighted by the failure of  431 
L1 subfragments, expressed as fusion proteins, to protect rabbits from papillomas and latency (Lin et al., 1993a).  The  432 
protection afforded by the full-length L1 fusion protein could be bypassed by DNA infection, indicating that viral  433 
particle uptake was being neutralised.  This protection was abolished by heat denaturation, indicating that the  434 
neutralisation epitopes were conformational.  Other means of generating viral proteins have proved successful in  435 
vaccination trials.  Vaccinia-expressed L1 generates an antibody response which inhibits papilloma formation in rabbits  436 
(Lin et al., 1992).    437 
  438 
In addition to the prophylactic immunity demonstrated for L1, the non-structural proteins E1, E2, and E6, but not E7,  439 
were found to enhance regression of viral papillomas (Lathe et al., 1989; Selvakumar et al., 1995b).  Vaccinated rabbits  440 
still developed warts as frequently as the controls, but these regressed more rapidly.  There was no correlation between  441 
antibody levels and regression, indicating that the response was cell-mediated.  These results contrast with those  442 
described below for BPV-4, in which therapeutic vaccination with E7, but not E2, is effective.  443 
  444 
Bacterial-expressed proteins and BPV vaccination  445 
BPV-2 L1 and L2 proteins expressed as E. coli β-galactosidase fusion proteins were trialled in calves (Jarrett et al.,  446 
1991).  Vaccination with L1, but not L2, generated serum-neutralising antibodies, and prevented tumour formation  447 
when given prophylactically.  L2 vaccination seemed to promote tumour regression, accompanied by tumour- 448  
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infiltrating lymphocytes, when given either prophylactically or after challenge.  L2 vaccination did stimulate antibody  449 
production, although these were ineffective at neutralisation, as assessed by a cell transformation inhibition assay.  The  450 
ability of L2 to cause regression is surprising since L2 appears not to be expressed in dividing cells.  It is possible that  451 
the response initiated by the L2 vaccine also stimulated a host response to other viral proteins as a bystander effect,  452 
causing regression.  Although BPV-2 L2 was not effective prophylactically, a later study was able to show protection  453 
from BPV-4 using an L2 fusion protein (Campo et al., 1993).  This later study used full-length L2, rather than the N- 454 
terminal truncated protein used with the BPV-2 trial.  Protection was mediated via neutralising antibodies to the N- 455 
terminal (Chandrachud et al., 1995; Gaukroger et al., 1996), a finding confirmed by the lack of neutralising ability of  456 
serum depleted of L2 antibodies.  Although antibodies were raised to the C-terminal region, they were not protective,  457 
perhaps because the C-terminal region is internal and interacts with DNA (Zhou et al., 1994).  Interestingly,  458 
unvaccinated infected calves did not develop antibodies to L2, indicating that it may not be well-recognised by the  459 
immune system during natural infection.  Antibodies to the amino-terminal of BPV-1 L2 react with BPV-1 virions and  460 
prevent in-vitro transformation by the virus (Roden et al., 1994a).  This study showed that some L1 monoclonal  461 
antibodies appeared to neutralise infection by a post-attachment mechanism, since binding of virions to the cell surface  462 
was not markedly inhibited.  Gaukroger and others (1996) reached a similar conclusion for BPV-4 L2 antibodies.  463 
  464 
As with the CRPV system, vaccination using fusion proteins from early viral genes has been evaluated in the bovine  465 
model.  Preliminary experiments with BPV-4 β-galactosidase fusion proteins failed to show an effect for E2.  In  466 
contrast with the failure of E7 to cause regression in rabbits, the BPV-4 E7 protein promoted early rejection when  467 
given either two weeks before or after challenge (Campo et al., 1993).  Further work with the BPV-4 E7 fusion protein  468 
mapped B- and T-cell epitopes and confirmed that the vaccine retarded papilloma development and promoted early  469 
regression in calves when given prior to challenge (Chandrachud et al., 1994; McGarvie et al., 1995).  Peripheral blood  470 
mononuclear cell proliferation assays demonstrated a positive response to E7 in the vaccinated group, as well as IgG  471 
antibody production by two weeks after boosting.  The E7 antibodies were not neutralising, and their role in regression  472 
is unknown.  Non-vaccinated infected cattle had only a weak cellular and humoral response to E7 which developed  473 
only during the later stages of infection.  Some unvaccinated infected animals appeared not to develop antibodies to E7  474 
(Chandrachud et al., 1994).  It seems likely that viral E7 is poorly presented to the immune system during natural  475 
infection.  476  
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  477 
Virus-like particles as vaccines  478 
Virus-like particles and COPV  479 
COPV L1 VLP vaccination protected dogs from infection (Ghim et al., 1995).  Serum from immune dogs protected  480 
naïve dogs in passive transfer experiments (Suzich et al., 1995; Ghim et al., 1997a).  A denatured L1 vaccine made  481 
antibodies but did not prevent infection, demonstrating the need for conformational epitopes.  HPV-11 L1-VLPs were  482 
not protective, demonstrating the type-specificity of the neutralising antibodies. VLPs made from the L1 protein of  483 
COPV display type-specific conformational epitopes (Chen et al., 1998).  The ability to form VLPs remains even when  484 
the protein is truncated sufficiently to abolish expression of the neutralising conformational epitopes, demonstrating  485 
that not all VLPs may be useful as vaccines.  486 
  487 
Virus-like particles and BPV  488 
The ability of BPV VLPs to generate serum neutralising antibodies was demonstrated by vaccination of rabbits  489 
followed by use of the serum for in vitro neutralisation assays.  The ability to neutralise virus depended upon  490 
conformational epitopes (Kirnbauer et al., 1992).  VLPs composed of either L1 alone or L1 with L2 were effective at  491 
generating antibody responses and preventing BPV-4 infection in calves.  The vaccines did not effectively initiate  492 
regression of established lesions, and although the lesions of vaccinated animals did show a tendency to regress more  493 
rapidly than those of controls this did not reach statistical significance (Kirnbauer et al., 1996).  As with COPV, this  494 
work with BPV-4 demonstrated the ability of VLPs to prevent mucosal papillomavirus infections.  495 
  496 
Virus-like particles and CRPV  497 
Vaccination with CRPV L1 VLPs made in yeast cells (Jansen et al., 1995), and CRPV L1 or L1-L2 VLPs made by  498 
baculovirus in insect cells (Breitburd et al., 1995; Christensen et al., 1996b) protects rabbits.  This protection is long- 499 
term, lasting for at least one year (Christensen et al., 1996b).  ELISA using native CRPV L1-L2 VLPs demonstrated a  500 
marked response within a week of the second boost, whereas control rabbits had only a smaller rise in antibody titre  501 
after CRPV challenge.  Protection is mediated via virus-neutralising IgG and requires a conformational epitope  502 
(Breitburd et al., 1995). Protection is type-specific, since BPV L1-L2 VLPs (Breitburd et al., 1995) and HPV-11 VLPs  503 
(Christensen et al., 1996b) failed to protect rabbits from experimental challenge.   504  
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  505 
Virus-like particles and EcPV  506 
Virus-like particles prepared from the L1 protein of equine cutaneous papillomavirus (EcPV-1) have been used as  507 
reagents for ELISA studies and generation of monoclonal antibodies (Ghim et al., 1997b).  Sarcoid or BPV-1 sera were  508 
not reactive with EcPV-1 VLPs.  The recombinant VLPs carried conformational type-specific epitopes as well as  509 
sequential type-specific epitopes on the surface and acted as an effective prophylactic vaccine.    510 
  511 
Other VLP-based vaccines  512 
The ability to delete portions of BPV-L1 without affecting its ability to form VLPs (Paintsil et al., 1996) enables  513 
various epitopes, up to 60 amino acids (Muller et al., 1997), to be incorporated into the particle as 360 copies.  This  514 
was put into practice using BPV-1 L1 VLPs carrying two different CTL epitopes, including one for HPV-16 E7, fused  515 
to the L1 C-terminus.  Immunised mice generated a CTL response to the E7 epitope as well as a neutralising antibody  516 
response to the BPV-1 VLPs.  The functional significance of the E7 CTL response was proven by the ability of  517 
immunised mice to resist challenge from an E7-transfected tumorigenic cell line (Peng et al., 1998).  Recent work has  518 
shown that chimaeric BPV-1 L1/E7 VLPs, administered intranasally to mice, resulted in both systemic and mucosal  519 
antibody production (Liu et al., 1999). The recent demonstration that oral delivery of VLPs in mice generated type- 520 
specific, conformationally-dependant antibodies, which had neutralising ability based on an in vitro assay (Rose et al.,  521 
1999), opens a further avenue for exploration in the field of VLP research. The ability of VLPs to be effective via  522 
several routes, and to act as chimaeric particles and deliver both systemic and mucosal immunity, demonstrates their  523 
flexibility and there is much current interest in the potential of VLP vaccines against human papillomavirus infections  524 
(reviewed in Schiller, 1999).    525 
  526 
DNA vaccination against animal papillomaviruses  527 
The induction of specific immunity after injection of antigen-encoding DNA into mouse skin heralded a novel  528 
approach to vaccination (Tang et al., 1992).  Both intramuscular injection and particle bombardment of skin are  529 
effective, and the immunity is long lasting (reviewed in Tuting et al., 1998).    530 
  531 
In a study investigating the immune response to nucleic-acid induced papillomas, the warts of two rabbits in an  532  
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experimental group regressed shortly after DNA inoculation (Evans and Ito, 1966).  This could have been a  533 
coincidental spontaneous regression, since there were no controls, but it stimulated thought as to the possibility of  534 
inducing immunity by DNA vaccination.  535 
  536 
In rabbits, cutaneous gene-gun delivery of DNA plasmids encoding the CRPV L1 capsid protein elicited a strong  537 
antibody response (Sundaram et al., 1996). The recent findings that intramuscular (Donnelly et al., 1996) and  538 
cutaneous gene gun (Sundaram et al., 1997) vaccination with a DNA plasmid encoding CRPV L1 were able to prevent  539 
infection in rabbits has broadened the options for vaccine development.  These studies have been extended recently to  540 
demonstrate protection after vaccination with a DNA plasmid encoding the E6 gene (Sundaram et al., 1998).   The  541 
DNA was attached to 1-3 µm gold particles and delivered into the dorsal skin by a helium-driven "gene-gun", with  542 
boosting three weeks later.  Antibodies to E6 were not detectable by ELISA after vaccination, but there was a greater  543 
E6-specific in vitro proliferative response in three of six E6 vaccinated rabbits compared with controls.  This response  544 
correlated with protection from subsequent viral challenge, with two rabbits showing complete protection, and one  545 
rabbit developing only two tiny papillomas out of nine challenged sites.  The remaining three vaccinated rabbits  546 
showed partial protection as judged by delayed onset and reduced number and size of papillomas. DNA vaccines  547 
encoding a combination of viral early proteins may prove more effective than vaccines based on single genes. This is  548 
suggested by recent work in the domestic rabbit (with CRPV challenge), in which DNA vaccination with a  549 
combination of genes encoding E1, E2, E6 and E7 proved appeared more effective than DNA vaccines encoding only a  550 
single protein (Han et al., 1999b). In Han’s study, gene-gun vaccination did not elicit detectable humoral responses to  551 
the encoded antigens, although T-cell lymphoproliferative responses were seen to each of the encoded antigens.  The  552 
lack of humoral response to the encoded antigens was seen when DNA was delivered by either intracutaneous gene gun  553 
(Han, et al., 1999b), or intramuscular injection (Han et al., 1999a).  554 
  555 
In addition to their ability to alter the course of cutaneous papillomavirus infections, DNA vaccines are also efficient  556 
prophylactically in mucosal papillomavirus models.  We have shown that vaccination of dogs, using a DNA construct  557 
encoding the L1 protein, elicits both humoral and cell-mediated immunity and is effective in preventing the  558 
development of oral papillomas after mucosal challenge with virus (unpublished observations).  Clearly, DNA vaccines  559 
have the potential to play an important role in the future armamentarium against papillomavirus infections.  560  
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  561 
6. CONCLUDING REMARKS  562 
In summary, in vitro and in vivo studies on both human and animal papillomaviruses show that antibody responses  563 
occur in the natural infection, and that antibodies to conformational epitopes on the viral capsid can neutralise viral  564 
infectivity in a type-specific manner.  Humoral immunity appears to play little part in wart regression.  Cellular  565 
immunity, however, is crucial in mediating wart regression, with E2 and E7 being implicated as important antigens.   566 
These findings are clearly of fundamental importance for vaccination development.  It should be borne in mind that  567 
immunological strategies may be less useful in those suffering from severe papillomavirus infections due to  568 
immunosuppression.  In this respect, it is noteworthy that not all wart regression need be mediated by the immune  569 
system.  There is evidence from studies in the rabbit that treatment of warts with podofilox causes regression by a  570 
direct toxic effect on keratinocytes, rather than by stimulation of host immunity (Okabayashi et al., 1993b).  Studies of  571 
natural and experimental disease in animals have demonstrated the basic roles of humoral and cellular immunity in  572 
prevention and regression of papillomavirus infections.  Additionally, the demonstration of effective prophylactic  573 
vaccination against bovine, canine and rabbit papillomaviruses holds some promise for reducing the impact of human  574 
papillomavirus-associated disease. Despite these successes, there remain many important issues to be addressed.  These  575 
include the role of cytokines in lesion regression, and their potential as immunomodulatory agents for therapeutic  576 
vaccination (Gaspari et al., 1997; Tan et al., 1999).  The availability of recombinant cytokines (Zucker et al., 1993;  577 
Okano et al., 1997) or reagents for the study of cytokines in animals (Buttner et al., 1998; Gröne et al, 1998) provides  578 
the tools for addressing some of these issues.  Novel methods of immunotherapy, including DNA vaccination, already  579 
show some promise in altering the course of papillomavirus infection in animals. Increased knowledge of the  580 
mechanisms underlying tolerance and immunity in animal disease models provides hope for the many people suffering  581 
the serious effects of human papillomavirus infection.  582 
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Figure legends  949 
Figure 1.  Spontaneous regression of canine oral papillomas.  950 
Experimentally, canine oral papillomas appear from 4 weeks after infection.  Early lesions are raised, multiple or  951 
confluent smooth nodules (a).  The mature papillomas appear at approximately 8 weeks (b) and are more pale and firm,  952  
  35 
with multiple projecting filiform papillae.  Regression occurs spontaneously, in this case starting at week 9, with a  953 
softening and shrinking of the papilloma (c).  The bulk of the papilloma then sloughs to leave a raised base (d) at 10  954 
weeks, which resorbs to leave normal intact mucosa.  Scale bars = 1 cm.  955 
  956 
Figure 2.  Naturally-occurring, non-regressing canine oral papillomatosis.   957 
 Occasionally spontaneous regression fails, with multiple crops of warts throughout the oral cavity (a), including the  958 
tongue and oesophagus (b).  959 
  960 
Figure 3. Papillomavirus virions.  961 
In the natural infection, virions are assembled in the nucleus of superficial keratinocytes within the stratum  962 
granulosum.  The virions are abundant, often forming crystalline arrays, as seen here.  Particles with similar  963 
morphology can be generated by in vitro expression of the L1 capsid protein, which then assembles spontaneously into  964 
virus-like particles (VLPs).  Bar = 1 μm.  965 
  966 
Figure 4.  967 
Cellular immunity in wart regression.  968 
Many species, including man, have lymphocytic infiltration in regressing warts.  In this example, from a dog, pre- 969 
infection control oral mucosa has only scant alpha/beta T cells in the epidermis and dermis (a).  During early wart  970 
regression, T cells begin to increase in number both intraepithelially and in the superficial dermis (b). x 20 objective.  971 
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